Nutra Pharma Corp. Reports Q2 2024 Financial Results with Increased Net Loss

Nutra Pharma Corp. reported its financial results for the second quarter of 2024, revealing a net loss of $367,139 for the three months ending June 30, compared to a loss of $279,246 during the same period in 2023. For the first half of 2024, the company recorded a net loss of $794,073, a decrease from the $871,806 loss reported in the first half of 2023. Revenue for the second quarter was $51,710, a slight decline from $52,398 in the prior year, while total revenue for the first six months of 2024 was $89,442, down from $106,920 in the same period last year. The decrease in revenue is attributed to a significant drop in sales to a related party, Avini Health, which accounted for 42% of total revenues in the second quarter, down from 63% in the same quarter of 2023.

The company’s total current assets increased to $359,886,000 as of June 30, 2024, compared to $314,060,000 at the end of 2023. This increase was primarily driven by a rise in accounts receivable and inventory. However, total liabilities also rose to $15,189,849, up from $14,408,705 at the end of the previous fiscal year, leading to a stockholders' deficit of $14,558,881. The company continues to face challenges with a working capital deficit of $14,640,377 and an accumulated deficit of $75,739,547, raising concerns about its ability to continue as a going concern.

Operationally, Nutra Pharma has made strategic moves, including the issuance of common stock for debt modification, which amounted to $3,500 during the second quarter. The company has also been focusing on its product lines, which include pain relief medications such as Cobroxin and Nyloxin, and has expanded its offerings to include products for pets and equine use. However, the company’s reliance on a single customer for a significant portion of its revenue poses risks, especially as Avini Health has begun manufacturing its own products, which is expected to further impact Nutra Pharma's sales.

Looking ahead, Nutra Pharma's management has indicated that the company will need to secure additional financing to sustain operations and execute its business plan. The company is currently exploring options for raising capital, including debt and equity funding, but faces limitations due to its stock being listed on the OTC Market Group’s Expert Market. The management has expressed uncertainty regarding the availability of future financing and the potential for increasing revenues and profitability, which are critical for the company's survival and growth in a competitive market.